Global acellular dermal matrices market is estimated to be valued at US$ 8.8 Bn in 2023, and is expected to exhibit a CAGR of 12.1% during the forecast period (2023-2030).
Report Coverage |
Report Details |
Base Year: |
2022 |
Market Size in 2023: |
US$ 8.8 Bn |
Historical Data for: |
2018 to 2021 |
Forecast Period: |
2023 - 2030 |
Forecast Period 2023 to 2030 CAGR: |
12.10% |
2030 Value Projection: |
US$ 19.6 Bn |
Figure 1. Global Acellular Dermal Matrices Market Share (%), By Origin, 2023
Acellular dermal matrix (ADM) is a soft connective tissue graft created by a decellularization procedure that leaves the extracellular skin matrix intact. This structure, once implanted in the body, acts as a scaffold for donor-side cells, facilitating future integration and revascularization. Initially, acellular dermal matrices were employed in burn resurfacing, abdominal wall repair, tympanic membrane replacement, dural repairs, and gingival grafting. ADMs are now mostly employed in breast surgery and plastic surgery. Furthermore, acellular dermal matrices are used for treating acute wounds such as burns, traumatic wounds, cancer, and infections, as well as chronic wounds such as diabetic foot ulcers, venous leg ulcers, pressure ulcers, and others.
Market Dynamics
Market players are engaged in new product launches or approvals for various applications such as tissue reconstruction, and this is expected to drive the global acellular dermal matrices market growth over the forecast period. For instance, in May 2023, AlloSource, one of the largest human tissue providers, launched the AlloMend Duo Acellular Dermal Matrix (ADM), a natural alternative for soft tissue restoration. The AlloMend Duo ADM was developed to assist surgeons in the repair and reconstruction of soft tissue abnormalities for long-term structural stability. The deep reticular dermal allograft integrates with the surrounding tissue, and acts as scaffold for cell repopulation and regeneration of the native host tissues.
The properties of AlloMend Duo ADM provide several advantages, and this makes it suitable for use in a variety of health treatments that need the strength and biocompatibility of a human regenerating tissue matrix. The allograft is flexible and pliable, allowing for ideal handling and accurate implantation.
Key features of the study:
- This report provides an in-depth analysis of the global acellular dermal matrices market and provides market size (US$ Bn) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global acellular dermal matrices market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Integra LifeSciences Corporation, AbbVie Inc., Johnson & Johnson, HansBioMed, Becton, Dickinson and Company, Cook Group, Smith & Nephew Plc., Reprise Biomedical, Organogenesis Holdings Inc., Tissue Regenix, LifeNet Health, Zimmer Biomet Holdings, Inc., Stryker Corporation, MiMedx Group, PolyNovo Limited, Fidia Pharma USA Inc., Baxter International Inc., In2Bones Global, BioHorizons, Inc., Harbor MedTech, Inc., MLM Biologics Inc., Geistlich Pharma AG, Olaregen Therapeutix, Inc., EnColl Corporation, Kerecis limited, DSM, ACell Inc., 3M, Cell Constructs I, LLC, CG bio Inc., and Marine Polymer Technologies, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global acellular dermal matrices market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global acellular dermal matrices market
Detailed Segmentation:
- Global Acellular Dermal Matrices Market, By Origin:
- Human Dermis
- Porcine Dermis
- Bovine Dermis
- Global Acellular Dermal Matrices Market, By Application:
- Acute Wounds
- Burns
- Trauma
- Cancers
- Infections
- Chronic Wounds
- Diabetic Foot Ulcers
- Venous Leg Ulcers
- Pressure Ulcer
- Others
- Reconstruction Procedures
- Abdominal Wall Procedures
- Breast Procedures
- Orthopedic Procedures
- Others
- Global Acellular Dermal Matrices Market, By Place of Setting:
- Hospitals
- In- patient
- Out- patient
- Ambulatory Surgical Centers
- Office Based
- Global Acellular Dermal Matrices Market, By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles
- Integra LifeSciences Corporation
- AbbVie Inc.
- Johnson & Johnson
- HansBioMed
- Becton, Dickinson and Company
- Cook Group
- Smith & Nephew Plc.
- Reprise Biomedical
- Organogenesis Holdings Inc
- Tissue Regenix
- LifeNet Health
- Zimmer Biomet Holdings, Inc.
- Stryker Corporation
- MiMedx Group
- PolyNovo Limited
- Fidia Pharma USA Inc.
- Baxter International Inc.
- In2Bones Global
- BioHorizons, Inc.
- Harbor MedTech, Inc.
- MLM Biologics Inc.
- Geistlich Pharma AG
- Olaregen Therapeutix, Inc.
- EnColl Corporation
- Kerecis limited
- DSM
- ACell Inc.
- 3M
- Cell Constructs I, LLC
- CG bio Inc.
- Marine Polymer Technologies, Inc.